Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial

Abbisko Cayman Limited has dosed the first U.S. patient in a global Phase I trial of irpagratinib, an FGFR4 inhibitor for advanced hepatocellular carcinoma. The drug has received Fast Track designation from the U.S. FDA and Breakthrough Therapy designation in China. Early data show durable antitumor activity and a favorable safety profile. Abbisko aims to accelerate global development and commercialization of irpagratinib, which shows promise in first-line HCC treatment. The current analyst rating for Abbisko stock (HK:2256) is a Hold with a price target of HK$13.00.